A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer

Ana M. Aparicio, Rebecca S.S. Tidwell, Shalini S. Yadav, Jiun Sheng Chen, Miao Zhang, Jingjing Liu, Shuai Guo, Patrick G. Pilié, Yao Yu, Xingzhi Song, Haswanth Vundavilli, Sonali Jindal, Keyi Zhu, Paul V. Viscuse, Justin M. Lebenthal, Andrew W. Hahn, Rama Soundararajan, Paul G. Corn, Amado Zurita-Saavedra, Sumit K. SubudhiJianhua Zhang, Wenyi Wang, Chad Huff, Patricia Troncoso, James P. Allison, Padmanee Sharma, Christopher J. Logothetis

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Purpose: To determine the efficacy and safety of risk-adapted combinations of androgen signaling inhibitors and inform disease classifiers for metastatic castration-resistant prostate cancers. Patients and Methods: In a modular, randomized phase II trial, 192 men were treated with 8 weeks of abiraterone acetate, prednisone, and apalutamide (AAPA; module 1) and then allocated to modules 2 or 3 based on satisfactory (≥50% PSA decline from baseline and <5 circulating tumor cell/7.5 mL) versus unsatisfactory status. Men in the former were randomly assigned to continue AAPA alone (module 2A) or with ipilimumab (module 2B). Men in the latter group had carboplatin + cabazitaxel added to AAPA (module 3). Optional baseline biopsies were subjected to correlative studies. Results: Median overall survival (from allocation) was 46.4 [95% confidence interval (CI), 39.2-68.2], 41.4 (95% CI, 33.3- 49.9), and 18.7 (95% CI, 14.3-26.3) months in modules 2A (n = 64), 2B (n = 64), and 3 (n = 59), respectively. Toxicities were within expectations. Of 192 eligible patients, 154 (80.2%) underwent pretreatment metastatic biopsies. The aggressive-variant prostate cancer molecular profile (defects in ≥2 of p53, RB1, and PTEN) was associated with unsatisfactory status. Exploratory analyses suggested that secreted phosphoprotein 1-positive and insulin-like growth factor-binding protein 2-positive macrophages, druggable myeloid cell markers, and germline pathogenic mutations were enriched in the unsatisfactory group. Conclusions: Adding ipilimumab to AAPA did not improve outcomes in men with androgen-responsive metastatic castration- resistant prostate cancer. Despite the addition of carboplatin + cabazitaxel, men in the unsatisfactory group had shortened survivals. Adaptive designs can enrich for biologically and clinically relevant disease subgroups to contribute to the development of marker-informed, risk-adapted therapy strategies in men with prostate cancer.

Original languageEnglish
Pages (from-to)2751-2763
Number of pages13
JournalClinical Cancer Research
Volume30
Issue number13
DOIs
StatePublished - 1 Jul 2024
Externally publishedYes

Fingerprint

Dive into the research topics of 'A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer'. Together they form a unique fingerprint.

Cite this